Bepharco (DBT) Sets 7% Stock Dividend, Record Date 16/11/2026
This Aveluro analysis covers DBT on HOSE in the Health Care sector. The classified event type is dividend announcement, with positive sentiment and a deterministic market-impact score of 4.0/10. Aveluro classifies this story as a positive catalyst in the stock's news coverage. Source coverage came from CafeF - Thị trường chứng khoán, classified as a primary/top-tier source.
Key Facts
Caveat: Not investment advice. · How Aveluro computed this: Aveluro combines extracted event facts, source credibility, ticker context, and market data. Scores are deterministic research signals, not recommendations.
Overview
Công ty Cổ phần Dược phẩm Bến Tre (Bepharco, ticker DBT on HOSE) has announced a 7% stock dividend for 2025, with a shareholder record date of 16/11/2026, alongside a change of Chief Accountant and the appointment of a new CEO. The issuance adds roughly 1.53 million shares and lifts charter capital from close to VND 219.7bn to about VND 235bn, making DBT one of the smaller HOSE-listed pharmaceutical names to combine a capital increase with a senior management reshuffle.
Key Facts
- Stock dividend ratio of 7%, meaning 100 shares held earn 7 new shares; record date 16/11/2026.
- Approximately 1.53 million new shares to be issued, funded from undistributed after-tax profit as of 31/12/2025 per the audited 2025 consolidated financial statements.
- Charter capital to rise from nearly VND 219.7bn to roughly VND 235bn if the full issuance completes.
- Nguyễn Thùy Dung steps down as Chief Accountant effective 2/11/2026; Nguyễn Nhật Phi appointed for a one-year term to 31/10/2027.
- Dung had registered to sell 14,687 DBT shares in October 2026 before leaving the role.
- Trần Ngô Minh Anh, born 2002, became CEO from 1/11/2026, succeeding Nguyễn Khắc Hanh, who resigned for personal reasons; the board approved her appointment on 23/10.
- H1 2026 net revenue reached nearly VND 418bn with net profit of close to VND 25bn; DBT closed at VND 13,150 on 28/10/2026, implying market capitalisation of about VND 288bn.
What Happened
Bepharco published a notice on the issuance of shares to pay the 2025 dividend and fixed the final registration date for shareholders to exercise their rights. The company said the 7% payout will be settled entirely in shares rather than cash, with the funding source drawn from retained after-tax profit recorded in the audited 2025 consolidated statements. The board resolution accompanying the announcement set the record date at 16/11/2026.
In the same disclosure, the board confirmed a change of Chief Accountant: Nguyễn Thùy Dung left the position on 2/11/2026 and Nguyễn Nhật Phi was appointed for a one-year term running to 31/10/2027. The filing also notes that Dung had registered to sell 14,687 DBT shares during October 2026, before her departure. Separately, on 23/10 the board approved the appointment of Trần Ngô Minh Anh as CEO from 1/11/2026, replacing Nguyễn Khắc Hanh, who resigned at his own request. Minh Anh, born in 2002, graduated in finance from the University of Central Florida and worked at New Omni Bank in California from 2024 to 2026; she joined Bepharco in August 2026, was elected to the board and named Deputy CEO before taking the top executive role. She is the daughter of Trần Ngô Phúc Vũ, Chairman of Nam A Bank.
Market Context
DBT closed at VND 13,150 on 28/10/2026, giving a market capitalisation of roughly VND 288bn, or about USD 11.5m at prevailing rates. The stock trades on HOSE within the small-cap pharmaceutical segment, a group that has generally lagged the index’s large-cap leadership through 2026 as investors favoured banks, brokers and property. A 7% share dividend is modest in value terms but mechanically dilutes the per-share price on the ex-date, and for a thinly traded name the more relevant signal is the governance change rather than the payout itself.
Strategic Significance
The strategic question for DBT is succession and control rather than the dividend. Handing the CEO role to a 2002-born executive with overseas banking experience, weeks after she joined the board, points to a founder-family transition at a company whose pharmaceutical manufacturing base dates to 1963. The link to the family of Nam A Bank’s chairman may eventually matter for DBT’s access to credit and distribution partnerships, though no such transaction has been disclosed. The 7% share dividend preserves cash — consistent with a company earning VND 25bn in H1 2026 — but it also spreads ownership across 1.53 million additional shares, which matters for a free float this small. Investors should treat the CFO exit and the pre-departure share sale as governance data points to weigh against the growth narrative.
What to Watch
- Confirmation of the amended charter capital and the official listing of the 1.53 million new shares on HOSE after the 16/11/2026 record date.
- The ex-dividend date and any adjustment to DBT’s reference price on HOSE.
- Q3 2026 results and whether H1 net profit of VND 25bn holds pace against the full-year plan.
- Disclosure of any related-party transactions involving Nam A Bank or the Trần Ngô family.
- Further management changes or share sales by senior officers following the CFO handover.